Caris Life Sciences Inc. (NASDAQ:CAI) on Thursday posted better-than-expected fourth-quarter earnings.
Caris Life Sciences on Thursday reported fourth-quarter earnings of 28 cents compared to the consensus loss of 3 cents. Sales for the quarter jumped 125% year over year to $292.89 million, beating the consensus of $208.63 million.
“Demand for our platform continued to accelerate in 2025, driving strong growth in volume and revenue and expanding adoption across our solutions. We are focused on building on this momentum, advancing our pipeline, and are particularly excited about the planned launch of our Caris Detect solution in the first half of 2026, which we believe represents a significant growth opportunity for Caris…,” said David Dean Halbert, Founder, Chairman, and CEO of Caris Life Sciences.
The company reported advancements in its multi-cancer early detection test, Caris Detect, which utilizes Whole Genome Sequencing to enhance early cancer detection capabilities, adding pressure as broader markets edged lower.
Caris Life Sciences shares jumped 14.1% to $21.95 in pre-market trading.
These analysts made changes to their price targets on Caris Life Sciences following earnings announcement.
- BTIG analyst Mark Massaro maintained Caris Life Sciences with a Buy and lowered the price target from $45 to $38.
- Baird analyst Catherine Schulte maintained the stock with an Outperform rating and raised the price target from $26 to $28.
- Evercore ISI Group analyst Vijay Kumar maintained the stock with an Outperform rating and lowered the price target from $38 to $34.
Considering buying CAI stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments